Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment1Abbreviations: AIA, antiinsulin antibody; CAPD, continuous ambulatory dialysis; CSII, continuous subcutaneous insulin infusion; DCCT, diabetes control complications trial; FIR, far infrared radiation; GLP1, glucagon-like peptide 1; GH, growth hormone; HbA1c, glycated hemoglobin; IDDM, insulin-dependent diabetes mellitus; IGF1, insulin-like growth factor 1; i.p., intraperitoneal; ISF, i

Jeandidier, N.; Boivin, S

doi:10.1016/s0169-409x(98)00072-6

Cited by 47 publications

(8 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10][11][12] In recent decades, a number of alternative insulin delivery methods involving micro-or nanotechnologies have been developed to overcome the limitations and drawbacks of conventional delivery. [13][14][15][16][17] Particularly, methods that can achieve non-invasive administration, 13,18 long-term release 19 or closed-loop based smart delivery 17,20 are highly desirable. They hold great potential to significantly improve the quality of life for diabetics.…”

Section: Introductionmentioning

confidence: 99%

Emerging micro- and nanotechnology based synthetic approaches for insulin delivery

et al. 2014

View full text Add to dashboard Cite

Insulin is essential for type 1 and advanced type 2 diabetics to maintain blood glucose levels and prolong lives. The traditional administration requires frequent subcutaneous insulin injections that are associated with poor patient compliance, including pain, local tissue necrosis, infection, and nerve damage. Taking advantage of emerging micro- and nanotechnologies, numerous alternative strategies integrated with chemical approaches for insulin delivery have been investigated. This review outlines recent developments in the controlled delivery of insulin, including oral, nasal, pulmonary, transdermal, subcutaneous and closed-loop insulin delivery. Perspectives from new materials, formulations and devices at the micro- or nano-scales are specifically surveyed. Advantages and limitations of current delivery methods, as well as future opportunities and challenges are also discussed.

show abstract

Section: Introductionmentioning

confidence: 99%

Emerging micro- and nanotechnology based synthetic approaches for insulin delivery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…For these patients, insulin treatment primarily requires self‐administration of multiple insulin injections throughout the day and regular monitoring of blood glucose (BG) levels (e.g., by finger‐prick blood tests) 3. Unfortunately, the insulin injection therapy is painful, inaccurate and often results in hypoglycemia if the insulin dosage is too high 4. It also requires a major commitment and discipline on the part of the patient.…”

Section: Introductionmentioning

confidence: 99%

Nanotechnology‐Enabled Closed Loop Insulin Delivery Device: In Vitro and In Vivo Evaluation of Glucose‐Regulated Insulin Release for Diabetes Control

Gordijo

Koulajian

Shuhendler

et al. 2010

Adv Funct Materials

122

101

View full text Add to dashboard Cite

Recently, a new multifunctional, bio‐inorganic nanocomposite membrane with the ability to self‐regulate the release of insulin in response to blood glucose (BG) levels was reported. Herein, the application of this material as part of a small, implantable, closed‐loop insulin delivery device designed to continuously monitor BG concentrations and regulate insulin release is proposed. The insulin delivery device consists of a nanocomposite glucose‐responsive plug covalently bound to an insulin reservoir made of surface‐modified silicone. The plug is prepared with crosslinked bovine serum albumin (BSA) and enzymes (glucose oxidase (GOx) and catalase (CAT)), pH‐responsive hydrogel nanoparticles, and multifunctional MnO2 nanoparticles. The plug functions both as a glucose sensor and controlled delivery unit to release higher rates of insulin from the reservoir in response to hyperglycemic BG levels and basal insulin rates at normal BG concentration. The surfaces of the device are modified by silanization followed by PEGylation to ensure its safety and biocompatibility and the stability of encased insulin. Our results show that insulin release can be modulated in vitro in response to glucose concentrations. In vivo experiments show that the glycemia of diabetic rats can be controlled with implantation of the prototype device. The glucose‐responsiveness of the device is also demonstrated by rapid drop in BG level after challenging diabetic rats with bolus injection of glucose solution. In addition, it is demonstrated that surface PEGylation of the device is necessary for reducing the immune response of the host to the implanted foreign object and maintaining insulin stability and bioactivity. With this molecular architecture and the bio‐inorganic nanocomposite plug, the device has the ability to maintain normal BG levels in diabetic rats.

show abstract

“…Many newer generation pens are able to deliver 60 U at a time for type 2 patients. Insulin pens have become very popular in some countries such as France where over 50 percent of insulin-treated patients are using insulin pens40. Some studies indicated wider acceptability in elderly and adolescent patients with respect to easier and faster injection and greater comfort41.…”

Section: Current Insulin Delivery Systemsmentioning

confidence: 99%

Recent challenges in insulin delivery systems: A review

Al-Tabakha¹,

Arida²

2008

Indian J Pharm Sci

View full text Add to dashboard Cite

Relatively, a large percentage of world population is affected by diabetes mellitus, out of which approximately 5-10% with type 1 diabetes while the remaining 90% with type 2. Insulin administration is essential for type 1 patients while it is required at later stage by the patients of type 2. Current insulin delivery systems are available as transdermal injections which may be considered as invasive. Several non-invasive approaches for insulin delivery are being pursued by pharmaceutical companies to reduce the pain, and hypoglycemic incidences associated with injections in order to improve patient compliance. While any new insulin delivery system requires health authorities' approval, to provide long term safety profile and insuring patients' acceptance. The inhalation delivery system Exubera® has already become clinically available in the United States and Europe for patients with diabetes as non-invasive delivery system.

show abstract

Cited by 47 publications

References 92 publications

Emerging micro- and nanotechnology based synthetic approaches for insulin delivery

Emerging micro- and nanotechnology based synthetic approaches for insulin delivery

Nanotechnology‐Enabled Closed Loop Insulin Delivery Device: In Vitro and In Vivo Evaluation of Glucose‐Regulated Insulin Release for Diabetes Control

Recent challenges in insulin delivery systems: A review

Contact Info

Product

Resources

About